Evidence map›Paper›PMID 42016308›Full record

ArticleiScience2026

NUP62 promotes breast cancer progression and inhibits ferroptosis by stabilizing NRF2 in a KEAP1-dependent way.

Ziran Qiu, Yu Lin, Shanzheng Chen, Wenqing Cao, Jun Yang, Rui Li, Yuan Chen, Xiaoqing Yao, Senlin Fu, Na Jin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziran QiuDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.
Yu LinDepartment of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Shanzheng ChenDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.
Wenqing CaoDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.
Jun YangDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.
Rui LiDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.
Yuan ChenDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.
Xiaoqing YaoDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.
Senlin FuDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.
Na JinDepartment of Breast and Thyroid Surgery, Loudi Central Hospital, No. 51, Changqing Middle Street, Loudi City, Hunan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Identification of drug resistance drivers of breast cancer (BC) is a multifaceted challenge. Here, we demonstrated that NUP62 is significantly upregulated in BC tissues and cell lines, and its high expression correlates with a poor prognosis. Functional experiments revealed that NUP62 promotes BC cell proliferation, migration, and malignant phenotypes, while inhibiting ferroptosis. Mechanistically, NUP62 competitively binds to KEAP1, disrupting KEAP1-mediated ubiquitination and degradation of NRF2. This stabilization promotes NRF2 nuclear translocation, enhancing the transcription of antioxidant genes and inhibiting ferroptosis. Crucially, eribulin-identified through virtual screening of FDA-approved compounds-selectively inhibited NUP62, destabilizing NRF2 and abrogating its nuclear localization.

Indexed as

cancermolecular biologypharmacology

Identifiers

PMID42016308
PMCPMC13092479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.